Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant TFPI (Concizumab Biosimilar) antibody

The Human Monoclonal anti-TFPI (Concizumab Biosimilar) antibody (ABIN7675920) specifically detects TFPI (Concizumab Biosimilar) in BLI, ELISA, FACS, Func and SPR. The antibody is reactive with Human samples.
Catalog No. ABIN7675920
-15% Promotion 2026
$294.23
$346.15
save $51.92 (-15 %)
Plus shipping costs $50.00
Shipping to: United States
Delivery in 10 to 11 Business Days

Quick Overview for Recombinant TFPI (Concizumab Biosimilar) antibody (ABIN7675920)

Target

TFPI (Concizumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 1
Human

Clonality

  • 1
Monoclonal

Conjugate

  • 1
This TFPI (Concizumab Biosimilar) antibody is un-conjugated

Application

Bio-Layer Interferometry (BLI), ELISA, Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
  • Expression System

    CHO Cells

    Purpose

    Anti-TFPI Reference Antibody (concizumab)

    Sequence

    EVQLVESGGG LVKPGGSLRL SCAASGFTFS NYAMSWVRQT PEKRLEWVAT ISRSGSYSYF PDSVQGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARLG GYDEGDAMDS WGQGTTVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK,DIVMTQTPLS LSVTPGQPAS ISCKSSQSLL ESDGKTYLNW YLQKPGQSPQ LLIYLVSILD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQATHFP QTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC

    Characteristics

    Anti-TFPI Reference Antibody (concizumab) is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.

    Purity

    >95 %

    Isotype

    IgG4 S228P
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Comment

    Therapeutic Agents by Target and Mechanism: TFPI inhibitors

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Concentration

    1 mg/mL

    Buffer

    25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

    Storage

    4 °C,-80 °C

    Storage Comment

    +4°C,-80°C
  • Target

    TFPI (Concizumab Biosimilar)

    Target Type

    Biosimilar

    Molecular Weight

    145.5 kDa

    UniProt

    P10646
You are here:
Chat with us!